Evidence map›Paper›PMID 24625754›Full record

ArticlePloS one2014

A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding.

Nathalie Wojtalewicz, Elham Sadeqzadeh, Jakob V Weiß, Mahnaz Moradian Tehrani, Susanne Klein-Scory, Stephan Hahn, Wolff Schmiegel, Uwe Warnken, Martina Schnölzer, Charles E de Bock and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. FAT1 Gene Expression in Iranian Acute Lymphoid and Myeloid Leukemia Patients.International journal of hematology-oncology and stem cell research · 2023
    Article
  7. Article
  8. Review
  9. ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage.Journal of the American Society of Nephrology : JASN · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Regulation of Alpha-Secretase ADAM10Frontiers in molecular neuroscience · 2017
    Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Nathalie WojtalewiczDepartment of Internal Medicine, IMBL, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Elham SadeqzadehSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.
Jakob V WeißDepartment of Internal Medicine, IMBL, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Mahnaz Moradian TehraniFunctional Proteome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Susanne Klein-ScoryDepartment of Internal Medicine, IMBL, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Stephan HahnDepartment of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany.
Wolff SchmiegelDepartment of Internal Medicine, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Uwe WarnkenFunctional Proteome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Martina SchnölzerFunctional Proteome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Charles E de BockCenter for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium.
Rick F ThorneSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, Australia.
Irmgard Schwarte-WaldhoffDepartment of Internal Medicine, IMBL, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany.
Ruhr University Bochum · DEHeidelberg University · DEUniversity of Newcastle Australia · AUGerman Cancer Research Center · DEVlaams Instituut voor Biotechnologie · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In pancreatic cancer, there is a clear unmet need to identify new serum markers for either early diagnosis, therapeutic stratification or patient monitoring. Proteomic analysis of tumor cell secretomes is a promising approach to indicate proteins released from tumor cells in vitro. Ectodomain shedding of transmembrane proteins has previously been shown to contribute significant fractions the tumor cell secretomes and to generate valuable serum biomarkers. Here we introduce a soluble form of the giant cadherin Fat1 as a novel biomarker candidate. Fat1 expression and proteolytic processing was analyzed by mass spectrometry and Western blotting using pancreatic cancer cell lines as compared to human pancreatic ductal epithelial cells. RNA expression in cancer tissues was assessed by in silico analysis of publically available microarray data. Involvement of ADAM10 (A Disintegrin and metalloproteinase domain-containing protein 10) in Fat1 ectodomain shedding was analyzed by chemical inhibition and knockdown experiments. A sandwich ELISA was developed to determine levels of soluble Fat1 in serum samples. In the present report we describe the release of high levels of the ectodomain of Fat1 cadherin into the secretomes of human pancreatic cancer cells in vitro, a process that is mediated by ADAM10. We confirm the full-length and processed heterodimeric form of Fat1 expressed on the plasma membrane and also show the p60 C-terminal transmembrane remnant fragment corresponding to the shed ectodomain. Fat1 and its sheddase ADAM10 are overexpressed in pancreatic adenocarcinomas and ectodomain shedding is also recapitulated in vivo leading to increased Fat1 serum levels in some pancreatic cancer patients. We suggest that soluble Fat1 may find an application as a marker for patient monitoring complementing carbohydrate antigen 19-9 (CA19-9). In addition, detailed analysis of the diverse processed protein isoforms of the candidate tumor suppressor Fat1 can also contribute to our understanding of cell biology and tumor behavior.

Indexed as

Gene Expression Regulation, NeoplasticADAM10 ProteinADAM ProteinsAdultAgedAged, 80 and overAmyloid Precursor Protein SecretasesCadherinsCase-Control StudiesCell Line, TumorFemaleGene Expression ProfilingGlycosylationHumansMaleMass SpectrometryADAM10 ProteinADAM10 protein, humanADAM ProteinsAmyloid Precursor Protein SecretasesCadherinsFAT1 protein, humanMembrane ProteinsRNA, Small Interfering

Identifiers

PMID24625754
PMCPMC3953070
OpenAlexW2020105998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.